<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by Professor John Collinge (CJD0003)</title></head><body><div><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Professor John Collinge (CJD0003)</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">John Collinge CBE MD DSc FRCP FRS FRCPath FMedSci</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor of Neurology, Head of Department of Neurodegenerative Disease and </span><span style="font-family:'Times New Roman'; font-size:11pt">Director of </span><span style="font-family:'Times New Roman'; font-size:11pt">the Medical Research</span><span style="font-family:'Times New Roman'; font-size:11pt"> Council (</span><span style="font-family:'Times New Roman'; font-size:11pt">MRC</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prion Unit, </span><span style="font-family:'Times New Roman'; font-size:11pt">UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1 3BG</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">This written evidence is provided at the request of the Science and Technology Committee secretariat. </span><span style="font-family:'Times New Roman'; font-size:11pt">I provide this evide</span><span style="font-family:'Times New Roman'; font-size:11pt">nce in a personal capacity and my view</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> are not necessarily those of the </span><span style="font-family:'Times New Roman'; font-size:11pt">Medical Research Council </span><span style="font-family:'Times New Roman'; font-size:11pt">or University College London. </span><span style="font-family:'Times New Roman'; font-size:11pt">I declare that I am a Director and Shareholder of D-Gen Limited, an academic spin-out company in the field of prion decontaminat</span><span style="font-family:'Times New Roman'; font-size:11pt">ion, diagnostics and therapeutics, the co-owners of which include MRC, Wellcome Trust, UCL and Imperial College London. </span><span style="font-family:'Times New Roman'; font-size:11pt">I was asked to respond to the following questions:</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt"></span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">What do you consider to be the likely prevalence of subclinical vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">infection in the UK population? What evidence is there to support this view?</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt"></span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">How might this subclinical infection rate translate to future cases of vCJD?</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> What are the key uncertainties in the relationship between subclinical and clinical vCJD?</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt"></span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">What are the likely routes of infection for vCJD? How have the potential modes of transmission changed over time?</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt"></span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">What procedures are currently in place to monitor, control and prevent further spread of vCJD across the UK population? Wha</span><span style="font-family:'Times New Roman'; font-size:11pt">t more could be done to reduce the risk posed by vCJD?</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Executive summary</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The b</span><span style="font-family:'Times New Roman'; font-size:11pt">est </span><span style="font-family:'Times New Roman'; font-size:11pt">available </span><span style="font-family:'Times New Roman'; font-size:11pt">estimate to date is that </span><span style="font-family:'Times New Roman'; font-size:11pt">around </span><span style="font-family:'Times New Roman'; font-size:11pt">1 in 2000 of UK population </span><span style="font-family:'Times New Roman'; font-size:11pt">are </span><span style="font-family:'Times New Roman'; font-size:11pt">infected with vCJD prions, a lethal pathogen</span><span style="font-family:'Times New Roman'; font-size:11pt">, following widespread exposure to BSE</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is unknown w</span><span style="font-family:'Times New Roman'; font-size:11pt">hat proportion </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">or which</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> of these infected individuals will develop clinical vCJD and after what length of time</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the range of </span><span style="font-family:'Times New Roman'; font-size:11pt">incubation periods </span><span style="font-family:'Times New Roman'; font-size:11pt">is </span><span style="font-family:'Times New Roman'; font-size:11pt">likely </span><span style="font-family:'Times New Roman'; font-size:11pt">to exceed </span><span style="font-family:'Times New Roman'; font-size:11pt">50 years</span><span style="font-family:'Times New Roman'; font-size:11pt">. M</span><span style="font-family:'Times New Roman'; font-size:11pt">any may </span><span style="font-family:'Times New Roman'; font-size:11pt">however </span><span style="font-family:'Times New Roman'; font-size:11pt">simply </span><span style="font-family:'Times New Roman'; font-size:11pt">be carriers and lead a full healthy lifespan</span><span style="font-family:'Times New Roman'; font-size:11pt"> but </span><span style="font-family:'Times New Roman'; font-size:11pt">all infected individuals </span><span style="font-family:'Times New Roman'; font-size:11pt">pose a </span><span style="font-family:'Times New Roman'; font-size:11pt">potential </span><span style="font-family:'Times New Roman'; font-size:11pt">risk to others if they become blood or organ donors and possibly via contamination of surgical instruments</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Several thousand UK individuals have been notified by the Health Protection Agency that they have been exp</span><span style="font-family:'Times New Roman'; font-size:11pt">osed to potentially contaminated blood, blood products or surgical instruments during routine NHS treatment and that they are at increased risk.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A range of m</span><span style="font-family:'Times New Roman'; font-size:11pt">easures to </span><span style="font-family:'Times New Roman'; font-size:11pt">reduce risk of prion transmission by blood and products have been introduced in the UK. </span><span style="font-family:'Times New Roman'; font-size:11pt">These measures have been very costly and remain of uncertain necessity or effectiveness.  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The key public health issue is what proportion of blood donors carry blood-borne vCJD prion infection and a prevalence study using a suitable blood test is needed</span><span style="font-family:'Times New Roman'; font-size:11pt"> to</span><span style="font-family:'Times New Roman'; font-size:11pt"> allow </span><span style="font-family:'Times New Roman'; font-size:11pt">more accurate </span><span style="font-family:'Times New Roman'; font-size:11pt">risk assessment and </span><span style="font-family:'Times New Roman'; font-size:11pt">effective </span><span style="font-family:'Times New Roman'; font-size:11pt">risk management</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A prototype vCJD blood test was developed by the MRC Prion Unit and is in </span><span style="font-family:'Times New Roman'; font-size:11pt">clinical </span><span style="font-family:'Times New Roman'; font-size:11pt">use for diagnosis of vCJD but has not yet been used for UK prevalence studies. A large scale anonymous co</span><span style="font-family:'Times New Roman'; font-size:11pt">mparison of blood samples from the UK and US (where population exposure to BSE has been minimal in comparison to UK) will be needed to establish whether the test detects carriers and to provide a preliminary estimate of prevalence of infection in the UK bl</span><span style="font-family:'Times New Roman'; font-size:11pt">ood supply. Results of such a study may then justify development of a </span><span style="font-family:'Times New Roman'; font-size:11pt">suitable </span><span style="font-family:'Times New Roman'; font-size:11pt">high</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">throughput</span><span style="font-family:'Times New Roman'; font-size:11pt"> blood test </span><span style="font-family:'Times New Roman'; font-size:11pt">which could be used to screen donated blood.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Effective means to decontaminate surgical and medical instruments by a simple pre-soak in an enzyme solution (akin to a biological washing powder) prior to routine sterilisation, developed at the request of, and funded by the Department of Health, has been</span><span style="font-family:'Times New Roman'; font-size:11pt"> available for years but not used in the NHS. Lack of NHS implementation has </span><span style="font-family:'Times New Roman'; font-size:11pt">precluded commercial </span><span style="font-family:'Times New Roman'; font-size:11pt">development of </span><span style="font-family:'Times New Roman'; font-size:11pt">a second generation product that could be incorporated in washer-disinfector machines for ease of use. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Prion diseases are now amongst the best</span><span style="font-family:'Times New Roman'; font-size:11pt"> understood causes of dementia and long term research at the MRC Prion Unit and elsewhere is leading to the development of potential treatments which could progress to clinical trials in the near future</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 10pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 10pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Response to questions from the Committee:</span></p><p style="margin:0pt 0pt 10pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt; font-weight:bold"></span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What do you consider to be the likely prevalence of subclinical vCJD infection in the UK population? What evidence is there to support this view?</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">The following background may be helpful:</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prions are infectious pathogens which cause lethal degenerative brain diseases in humans and other mammalian species. These diseases include scrapie in sheep </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> goats, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease in human</span><span style="font-family:'Times New Roman'; font-size:11pt">s. Prions are distinct from other infectious agents in </span><span style="font-family:'Times New Roman'; font-size:11pt">that they </span><span style="font-family:'Times New Roman'; font-size:11pt">lack their own genetic material. They are thought to be composed of misfolded and aggregated form</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> of one of the body’s own proteins, the prion protein, and propagate by a process of seeded p</span><span style="font-family:'Times New Roman'; font-size:11pt">rotein polymerisation</span><span style="font-family:'Times New Roman'; font-size:11pt"> (for review see</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The prion proteins in different mammalian species are closely similar in structure and p</span><span style="font-family:'Times New Roman'; font-size:11pt">rions from one species are able to infect another although usu</span><span style="font-family:'Times New Roman'; font-size:11pt">ally with much lower efficiency than between individuals of the same species.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Variant Creutzfeldt-Jakob disease (vCJD) </span><span style="font-family:'Times New Roman'; font-size:11pt">was first recognised in the UK in 1995 and </span><span style="font-family:'Times New Roman'; font-size:11pt">is caused </span><span style="font-family:'Times New Roman'; font-size:11pt">by </span><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">strain of prions quite distinct from those causing classical CJD and which was </span><span style="font-family:'Times New Roman'; font-size:11pt">shown to the same as that causing BSE</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2-4</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Exposure of the UK population to BSE prions via dietary and other routes was widespre</span><span style="font-family:'Times New Roman'; font-size:11pt">ad. It is estimated that up to three million UK cattle were infected with BSE of which around 750,000 were slaughtered for human consumption</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span><span style="font-family:'Times New Roman'; font-size:11pt">. In addition to primary infections from direct dietary or other exposure to BSE prions, concerns of secondary, human-to-human transmission have </span><span style="font-family:'Times New Roman'; font-size:11pt">affected endoscopy, ophthalmology, surgery, dentistry, organ transplantation, blood products/transfusion, and emerging stem cell therapies. S</span><span style="font-family:'Times New Roman'; font-size:11pt">econdary </span><span style="font-family:'Times New Roman'; font-size:11pt">infe</span><span style="font-family:'Times New Roman'; font-size:11pt">ctions have </span><span style="font-family:'Times New Roman'; font-size:11pt">been documented from use of contaminated blood and blood products</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">6-8</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Although the number of clinically recognised patients with vCJD has been thankfully relatively small (~200), the number of silent infections </span><span style="font-family:'Times New Roman'; font-size:11pt">appears to be </span><span style="font-family:'Times New Roman'; font-size:11pt">far l</span><span style="font-family:'Times New Roman'; font-size:11pt">arger.</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">P</span><span style="font-family:'Times New Roman'; font-size:11pt">rion infections are associated with long </span><span style="font-family:'Times New Roman'; font-size:11pt">asymptomatic incubation periods. Studies of the epidemic prion disease kuru in Papua New Guinea</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and of iatrogenic CJD resulting from exposure to contaminated human growth hormone</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> demonstrate incubation periods spanning decades</span><span style="font-family:'Times New Roman'; font-size:11pt">. Cases of iatrogenic CJD oc</span><span style="font-family:'Times New Roman'; font-size:11pt">cur every year in the UK, with recent incubation times estimated to be over 35 years. Approximately 3% of patients exposed to human growth hormone have developed clinical disease. I</span><span style="font-family:'Times New Roman'; font-size:11pt">ncubation periods in excess of 50 years have been documented in kuru</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">9</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">It is important also to appreciate that these incubation periods arise from same species (human-to-human) </span><span style="font-family:'Times New Roman'; font-size:11pt">transmission, cross-species transmissions are typically associated with much longer incubation periods which may approach the natural lifespan of the species concerned. </span><span style="font-family:'Times New Roman'; font-size:11pt">Another important consideration is that </span><span style="font-family:'Times New Roman'; font-size:11pt">it has been know</span><span style="font-family:'Times New Roman'; font-size:11pt">n</span><span style="font-family:'Times New Roman'; font-size:11pt"> for some years that infection</span><span style="font-family:'Times New Roman'; font-size:11pt"> of animals with prions from another species can result in a long</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">term infection or carrier state. Such subclinically infected animals may not develop the neurological disease during their lifespan but develop high levels of infectious prions. Transmission</span><span style="font-family:'Times New Roman'; font-size:11pt"> of such prions to more animals of the same species is typically associated with 100% lethality</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">10</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><br style="page-break-before:always; clear:both" /><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">UK prevalence estimates</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">My laboratory reported in 1997 that in vCJD, in sharp contrast to classical CJD where prio</span><span style="font-family:'Times New Roman'; font-size:11pt">ns are largely confined to the brain and spinal cord, prions were </span><span style="font-family:'Times New Roman'; font-size:11pt">much </span><span style="font-family:'Times New Roman'; font-size:11pt">more widespread </span><span style="font-family:'Times New Roman'; font-size:11pt">in the body </span><span style="font-family:'Times New Roman'; font-size:11pt">and may be readily detected in so-called lymphoreticular tissues including the tonsil </span><span style="font-family:'Times New Roman'; font-size:11pt">and appendix</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">11, 12</span><span style="font-family:'Times New Roman'; font-size:11pt">. I </span><span style="font-family:'Times New Roman'; font-size:11pt">suggested at</span><span style="font-family:'Times New Roman'; font-size:11pt"> that time to the Department of Health that this finding potentially allowed an estimate of the prevalence</span><span style="font-family:'Times New Roman'; font-size:11pt"> of silent vCJD prion infection in the community by an anonymous screen of archived or discarded surgical appendix or tonsil specimens. </span><span style="font-family:'Times New Roman'; font-size:11pt">A number of such studies have since been conducted</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">13-17</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A retrospective study of 12,674 archived surgical lymphoret</span><span style="font-family:'Times New Roman'; font-size:11pt">icular specimens (predominantly appendix) in 2004 found three positives and estimated a prevalence of infection in the UK population of 237 per million (95% confidence interval 49-692 per million)</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">14</span><span style="font-family:'Times New Roman'; font-size:11pt">. Based on this study a prevalence estima</span><span style="font-family:'Times New Roman'; font-size:11pt">te of 1 in 4000 was recommended by the </span><span style="font-family:'Times New Roman'; font-size:11pt">former </span><span style="font-family:'Times New Roman'; font-size:11pt">Spongiform Encephalopathy Advisory Committee (SEAC) for managing public health risks</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">18, 19</span><span style="font-family:'Times New Roman'; font-size:11pt">. Further studies of tonsil specimens did not significantly refine these estimates</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">15, 16</span><span style="font-family:'Times New Roman'; font-size:11pt"> and a further study was initiated by the Health Protection Agency (HPA) on advice from SEA</span><span style="font-family:'Times New Roman'; font-size:11pt">C with the aim of analysing a minimum of 30,000 appendix samples. The study found 16 definite positive appendices out of 32,441 suitable samples examined</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> equating to a final prevalence estimate of 493 per million (95% CI: 282 to 801 per million)</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">17</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per </span><span style="font-family:'Times New Roman'; font-size:11pt">million) and was similar in both sexes and across the three broad geographical areas sampled. </span><span style="font-family:'Times New Roman'; font-size:11pt"> This rate is consistent with the range of previous studies but is more precise and has a higher central estimate of around 1 infection in 2000</span><span style="font-family:'Times New Roman'; font-size:11pt"> equating to around</span><span style="font-family:'Times New Roman'; font-size:11pt"> 20-30,000 infected carriers in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The extraordinary range of incubation periods seen in natural human prion infections and the existence of subclinical carrier states in animal models exposed to prions from another species offer potential explanatio</span><span style="font-family:'Times New Roman'; font-size:11pt">ns for the huge discrepancy between estimates of infection prevalence and clinical cases</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">20</span><span style="font-family:'Times New Roman'; font-size:11pt">. While such carriers may live a normal lifespan without overt neurological disease, same species subpassage of infectivity is associated with 100% lethality</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">10</span><span style="font-family:'Times New Roman'; font-size:11pt"> arguing that asymptomatic human carriers would pose a distinct risk of transferring a fatal prion infection to others via medical and surgical procedures. Although the risks of iatrogenic prion transmission through s</span><span style="font-family:'Times New Roman'; font-size:11pt">urgery and solid organ transplantation should not be underestimated, the greatest threat to public safety is thought to be posed by the transfusion of prion-infected blood. The reality of vCJD transmission by this route has been known for some years and st</span><span style="font-family:'Times New Roman'; font-size:11pt">udy of a small cohort known to have received blood from donors who subsequently developed vCJD suggests the risk is very high to such recipients</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">6, 7, 21</span><span style="font-family:'Times New Roman'; font-size:11pt">. Emerging experimental evidence from sheep scra</span><span style="font-family:'Times New Roman'; font-size:11pt">pie</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">22</span><span style="font-family:'Times New Roman'; font-size:11pt"> (thought to be a good model of vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">) are unexpectedly indicating blood transfusion may be a more efficient infection route than direct inoculation into the brain. Indeed, as little as 200</span><span style="font-family:Symbol; font-size:11pt"></span><span style="font-family:'Times New Roman'; font-size:11pt">l of infected blood is </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">fficient in transmitting disease by transfusion in sheep</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">23</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">It is conceivable that there could be some hitherto unknown explanation for abnormal PrP in the appendix, unrelated to vCJD prion infection (</span><span style="font-family:'Times New Roman'; font-size:11pt">that is, </span><span style="font-family:'Times New Roman'; font-size:11pt">false positive</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">). Further work looking at this possibility is being done by HPA using</span><span style="font-family:'Times New Roman'; font-size:11pt"> appendices removed before the BSE epidemic. However, b</span><span style="font-family:'Times New Roman'; font-size:11pt">ased on a wealth of data from examination of </span><span style="font-family:'Times New Roman'; font-size:11pt">humans and animal tissues</span><span style="font-family:'Times New Roman'; font-size:11pt">, a</span><span style="font-family:'Times New Roman'; font-size:11pt">bnormal </span><span style="font-family:'Times New Roman'; font-size:11pt">prion protein </span><span style="font-family:'Times New Roman'; font-size:11pt">in the appendix </span><span style="font-family:'Times New Roman'; font-size:11pt">is highly likely to be an accurate </span><span style="font-family:'Times New Roman'; font-size:11pt">diagnostic </span><span style="font-family:'Times New Roman'; font-size:11pt">marker for vCJD infection. </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">t should be note</span><span style="font-family:'Times New Roman'; font-size:11pt">d that even the alarming estimate of 1 in 2000 infections in the UK population </span><span style="font-family:'Times New Roman'; font-size:11pt">could </span><span style="font-family:'Times New Roman'; font-size:11pt">be an underestimate since the sensitivity of the method used on appendix samples in carriers is not known and there could be significant numbers of false negative</span><span style="font-family:'Times New Roman'; font-size:11pt"> (true ca</span><span style="font-family:'Times New Roman'; font-size:11pt">rriers in which abnormal prion protein is not detected in the appendix by these methods)</span><span style="font-family:'Times New Roman'; font-size:11pt">, indeed disease-related PrP is sometimes not detected in appendix samples </span><span style="font-family:'Times New Roman'; font-size:11pt">from</span><span style="font-family:'Times New Roman'; font-size:11pt"> patients who have died of definite vCJD </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">24</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In summary, our best estimate today is that ~1 in 2000 of the UK population is infected with vCJD prions. However, it is important to understand that what is really important from a public health risk management perspecti</span><span style="font-family:'Times New Roman'; font-size:11pt">ve is how many people ha</span><span style="font-family:'Times New Roman'; font-size:11pt">ve</span><span style="font-family:'Times New Roman'; font-size:11pt"> detectable prions in their blood rather </span><span style="font-family:'Times New Roman'; font-size:11pt">than </span><span style="font-family:'Times New Roman'; font-size:11pt">a</span><span style="font-family:'Times New Roman'; font-size:11pt">ppendix </span><span style="font-family:'Times New Roman'; font-size:11pt">since it is blood that presents the greatest risk of transmission to others. Consequently, </span><span style="font-family:'Times New Roman'; font-size:11pt">prevalence studies using a blood test are </span><span style="font-family:'Times New Roman'; font-size:11pt">also </span><span style="font-family:'Times New Roman'; font-size:11pt">needed (see below).  </span></p><p style="margin:0pt 0pt 10pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt; font-weight:bold"></span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">How </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">might this subclinical infection rate translate to future cases of vCJD?</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> What are the key uncertainties in the relationship between subclinical and clinical vCJD?</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In order to predict the number of future cases of vCJD we </span><span style="font-family:'Times New Roman'; font-size:11pt">would </span><span style="font-family:'Times New Roman'; font-size:11pt">need to know </span><span style="font-family:'Times New Roman'; font-size:11pt">what </span><span style="font-family:'Times New Roman'; font-size:11pt">proportion</span><span style="font-family:'Times New Roman'; font-size:11pt"> of subclinical carriers will develop clinical disease, the</span><span style="font-family:'Times New Roman'; font-size:11pt"> range of </span><span style="font-family:'Times New Roman'; font-size:11pt">incubation </span><span style="font-family:'Times New Roman'; font-size:11pt">periods</span><span style="font-family:'Times New Roman'; font-size:11pt">, and the mortality from other causes in this group</span><span style="font-family:'Times New Roman'; font-size:11pt"> prior to the development of clinical prion disease</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">It is possible that, as in some animal models, many of these indi</span><span style="font-family:'Times New Roman'; font-size:11pt">viduals will be healthy carriers throughout their lives even if they live to advanced age. However, it will be many years before we know how many such subclinically infected individuals </span><span style="font-family:'Times New Roman'; font-size:11pt">ultimately </span><span style="font-family:'Times New Roman'; font-size:11pt">develop disease. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Recently published </span><span style="font-family:'Times New Roman'; font-size:11pt">experiments in mice th</span><span style="font-family:'Times New Roman'; font-size:11pt">at were genetically engineered to </span><span style="font-family:'Times New Roman'; font-size:11pt">make </span><span style="font-family:'Times New Roman'; font-size:11pt">human prion protein showed that inoculation of these animals with vCJD usually result</span><span style="font-family:'Times New Roman'; font-size:11pt">ed</span><span style="font-family:'Times New Roman'; font-size:11pt"> in prion infection in </span><span style="font-family:'Times New Roman'; font-size:11pt">lymphoreticular </span><span style="font-family:'Times New Roman'; font-size:11pt">tissue, </span><span style="font-family:'Times New Roman'; font-size:11pt">but </span><span style="font-family:'Times New Roman'; font-size:11pt">only a minority of </span><span style="font-family:'Times New Roman'; font-size:11pt">these </span><span style="font-family:'Times New Roman'; font-size:11pt">animals developed clinical disease in their lifetime</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">25</span><span style="font-family:'Times New Roman'; font-size:11pt">. These experiments are a striking parallel with the current situation in the UK with a remarkably high prevalence of vCJD infection, but a much lower incidence of clinical disease</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">20</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We do not under</span><span style="font-family:'Times New Roman'; font-size:11pt">stand what determin</span><span style="font-family:'Times New Roman'; font-size:11pt">es whether a person will </span><span style="font-family:'Times New Roman'; font-size:11pt">remain a </span><span style="font-family:'Times New Roman'; font-size:11pt">healthy carrier</span><span style="font-family:'Times New Roman'; font-size:11pt"> of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion infection or develop </span><span style="font-family:'Times New Roman'; font-size:11pt">the clinical state, for example whether there are environmental triggers that might lead to a carrier developing the disease. We do know</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> however</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> of powerful genetic factors that affect susceptibility to, and incubation periods, of prion diseases including vCJD. </span><span style="font-family:'Times New Roman'; font-size:11pt">The most important of these is a polymorphism in the human prion protein itself which exists in two common forms known as M and V so there</span><span style="font-family:'Times New Roman'; font-size:11pt"> are three genetic types in the population: MM, MV and VV</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">26, 27</span><span style="font-family:'Times New Roman'; font-size:11pt">. All definite vCJD patients to date have been MM (a genetic type seen in abou</span><span style="font-family:'Times New Roman'; font-size:11pt">t a third of the population). It is likely that clinical cases will occur in the other genotypes (VV and MV) but may have longer average incubation periods and also may present with a different pattern of disease that may not meet the diagnostic criteria o</span><span style="font-family:'Times New Roman'; font-size:11pt">f vCJD and indeed may be mistaken for classical CJD</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">28, 29</span><span style="font-family:'Times New Roman'; font-size:11pt">. One pa</span><span style="font-family:'Times New Roman'; font-size:11pt">tient with probable vCJD was of the MV genotype</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">30</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">All three genotypes were represented in the 16 appendices found to show subclinical vCJD infection in the HPA prevalence </span><span style="font-family:'Times New Roman'; font-size:11pt">studies. </span><span style="font-family:'Times New Roman'; font-size:11pt">Other genes have been identified with an effect on disease susceptibility or incubation period (for review see</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">31</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 10pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Symbol; font-size:11pt; font-weight:bold"></span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the likely routes of infection for vCJD? How have the potential modes of transmission changed over time?</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The most likely cause of the primary epidemic of vCJD was </span><span style="font-family:'Times New Roman'; font-size:11pt">dietary </span><span style="font-family:'Times New Roman'; font-size:11pt">exposure to food products </span><span style="font-family:'Times New Roman'; font-size:11pt">containing brain or spinal cord tissues from cattle </span><span style="font-family:'Times New Roman'; font-size:11pt">infected with BSE. </span><span style="font-family:'Times New Roman'; font-size:11pt">BSE prions also readily infect sheep and it is conceivable sheep-passaged BSE prions could also have been involved. Bovine products were widely used for other </span><span style="font-family:'Times New Roman'; font-size:11pt">purposes, for instance in cosmetics and production of certain medicines including vaccines although no epidemiological link with vCJD has been demonstrated. The number of primary vCJD cases has fallen steadily in recent years. Secondary </span><span style="font-family:'Times New Roman'; font-size:11pt">transmission </span><span style="font-family:'Times New Roman'; font-size:11pt">is now</span><span style="font-family:'Times New Roman'; font-size:11pt"> the principal concern </span><span style="font-family:'Times New Roman'; font-size:11pt">through blood</span><span style="font-family:'Times New Roman'; font-size:11pt">, blood products, tissue or organ donation and contamination of surgical (including dental) instruments</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">While transmission of classical CJD by surgical instruments and tissue grafts has been well documented, to date vCJ</span><span style="font-family:'Times New Roman'; font-size:11pt">D transmission between humans has only been documented by via blood transfusion and use of blood products. However, the apparently high carrier state of vCJD prion infection in the UK population and much wider distribution of prions outside the brain and s</span><span style="font-family:'Times New Roman'; font-size:11pt">pinal cord in vCJD would argue that secondary vCJD cases arising from contaminated surgical instruments or tissue or organ transplantation should be anticipated in the years ahead. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:Symbol; font-size:11pt; font-weight:bold"></span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What procedures are currently in place to monitor, control and p</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">revent further spread of vCJD across the UK population? What more could be done to reduce the risk posed by vCJD?</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Monitoring of vCJD clinical incidence is primarily the responsibility of the National CJD Research and Surveillance Unit </span><span style="font-family:'Times New Roman'; font-size:11pt">(NCJDRSU) </span><span style="font-family:'Times New Roman'; font-size:11pt">in Edinburg</span><span style="font-family:'Times New Roman'; font-size:11pt">h. Most cases are identified following the referral of </span><span style="font-family:'Times New Roman'; font-size:11pt">suspect cases by local neurologists, psychiatrists, general physicians and GPs to NCJDRSU or the NHS National Prion Clinic</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt">NPC</span><span style="font-family:'Times New Roman'; font-size:11pt">) in London</span><span style="font-family:'Times New Roman'; font-size:11pt">. Telephone conversations several times weekly, and a formal mo</span><span style="font-family:'Times New Roman'; font-size:11pt">nthly meeting between </span><span style="font-family:'Times New Roman'; font-size:11pt">the NCJDRSU and NPC</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">ensures complete case coordination. There are concerns that cases </span><span style="font-family:'Times New Roman'; font-size:11pt">might be missed in elderly patients</span><span style="font-family:'Times New Roman'; font-size:11pt"> where other causes of dementia are common</span><span style="font-family:'Times New Roman'; font-size:11pt">, either because the classical clinical features of </span><span style="font-family:'Times New Roman'; font-size:11pt">v</span><span style="font-family:'Times New Roman'; font-size:11pt">CJD are not manif</span><span style="font-family:'Times New Roman'; font-size:11pt">est, or that investigations required to raise concerns about CJD are not requested, or are misinterpreted. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Several measures have been taken to minimise the risks of transmission by blood </span><span style="font-family:'Times New Roman'; font-size:11pt">transfusion </span><span style="font-family:'Times New Roman'; font-size:11pt">or </span><span style="font-family:'Times New Roman'; font-size:11pt">use of </span><span style="font-family:'Times New Roman'; font-size:11pt">blood product</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The ongoing disruption and cos</span><span style="font-family:'Times New Roman'; font-size:11pt">ts to the NHS as a consequence of </span><span style="font-family:'Times New Roman'; font-size:11pt">these </span><span style="font-family:'Times New Roman'; font-size:11pt">measures</span><span style="font-family:'Times New Roman'; font-size:11pt"> -</span><span style="font-family:'Times New Roman'; font-size:11pt"> of uncertain efficacy or necessity</span><span style="font-family:'Times New Roman'; font-size:11pt"> -</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">are</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">remarkable. From 1997-2005 a series of measures were introduced, including leucodepletion of blood, sourcing of plasma from non-UK sources, exclusion of transfusion</span><span style="font-family:'Times New Roman'; font-size:11pt"> recipients from donation, use of recombinant clotting factors for patients with bleeding disorders and ceasing the use of UK plasma for fractionation and export</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">32</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">In 2010 the cumulative costs to the NHS Blood and Transfusion service were estimated at £540M, with a recurrent annual cost of £40M. Costs associated</span><span style="font-family:'Times New Roman'; font-size:11pt"> with other parts of the NHS have not been precisely estimated, however, the recurrent annual cost of synthetic clotting factors for patients with bleeding disorders is approximately £200M</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">33</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">Concern regarding secondary transmission of vCJD has also had major effects on public health policy internationally. For exa</span><span style="font-family:'Times New Roman'; font-size:11pt">mple, the USA and Australia exclude those with a cumulative residence of six months or more in Europe as blood donors</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> with considerable disruption to the blood supply in some areas</span><span style="font-family:'Times New Roman'; font-size:11pt"> and for the US military</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">What more could be done to reduce the risk posed</span><span style="font-family:'Times New Roman'; font-size:11pt"> by vCJD? Risk could be effectively managed by: </span><span style="font-family:'Times New Roman'; font-size:11pt">(i) </span><span style="font-family:'Times New Roman'; font-size:11pt">the development of a blood test to allow screening of donated blood for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">prion </span><span style="font-family:'Times New Roman'; font-size:11pt">infection </span><span style="font-family:'Times New Roman'; font-size:11pt">thereby allowing exclusion of infected units from use for blood transfusion or production of blood products; (i</span><span style="font-family:'Times New Roman'; font-size:11pt">i) screening patients due to undergo certain surgical procedures involving tissues at higher risk for prion infection (for example brain, spinal cord, the back of the eye, or certain dental procedures involving nervous tissue) so that particular precaution</span><span style="font-family:'Times New Roman'; font-size:11pt">s could be taken with those testing positive to minimise risk of infection of other patients; (iii) use of effective prion decontamination methods </span><span style="font-family:'Times New Roman'; font-size:11pt">to prevent vCJD transmission on surgical instruments</span><span style="font-family:'Times New Roman'; font-size:11pt"> (prions </span><span style="font-family:'Times New Roman'; font-size:11pt">stick avidly to surgical stainless steel and oth</span><span style="font-family:'Times New Roman'; font-size:11pt">er surfaces and </span><span style="font-family:'Times New Roman'; font-size:11pt">are partially resistant to normal hospital sterilisation methods)</span><span style="font-family:'Times New Roman'; font-size:11pt">; (iv) effective treatments for prion infection are being developed and might allow not only treatment of patients with the disease, but also treatment of asymptomatic infecte</span><span style="font-family:'Times New Roman'; font-size:11pt">d individuals (for example those testing positive on suitable blood or other tests) to eradicate the infection before symptoms develop.</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Over a decade ago, </span><span style="font-family:'Times New Roman'; font-size:11pt">the Department of Health invited and funded a large number of research proposals to develop novel met</span><span style="font-family:'Times New Roman'; font-size:11pt">hods for prion decontamination. This led to several products that might be used in a hospital environment. The MRC Prion Unit undertook a significant research project funded by this programme and developed an effective enzyme/detergent mixture that effecti</span><span style="font-family:'Times New Roman'; font-size:11pt">vely destroyed prions on metal surfaces</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">34, 35</span><span style="font-family:'Times New Roman'; font-size:11pt">. We were successful in obtaining an industrial partner (DuPont) to turn this laboratory research into a practical product but this was not used in the NHS and is no longer in produ</span><span style="font-family:'Times New Roman'; font-size:11pt">ction. The product was formulated for use as a </span><span style="font-family:'Times New Roman'; font-size:11pt">simple </span><span style="font-family:'Times New Roman'; font-size:11pt">pre-soak to prion decontaminate instruments before they went into the standard hospital washer</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">disinfector machines. The </span><span style="font-family:'Times New Roman'; font-size:11pt">lack</span><span style="font-family:'Times New Roman'; font-size:11pt"> of take up of this or other prion decontamination technologies </span><span style="font-family:'Times New Roman'; font-size:11pt">in the NHS </span><span style="font-family:'Times New Roman'; font-size:11pt">probably</span><span style="font-family:'Times New Roman'; font-size:11pt"> precluded further commercial investment to develop a second generation product which might have been integrate</span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt"> into washer</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">disinfector</span><span style="font-family:'Times New Roman'; font-size:11pt"> cycles for </span><span style="font-family:'Times New Roman'; font-size:11pt">improved</span><span style="font-family:'Times New Roman'; font-size:11pt"> ease of use. </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Extensive research effort internationally has gone into developing a blood te</span><span style="font-family:'Times New Roman'; font-size:11pt">st for vCJD. My Unit developed the first such test which was reported in the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> in 2011</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">36</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt"> discussed the test at high level with the Department of Health (Public Health Minister and Chief Medical Officer) in 2011 who advised they were not in </span><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">position to fund further evaluation or pre</span><span style="font-family:'Times New Roman'; font-size:11pt">valence screening and recommended transfer to a commercial partner. Despite further discussions with diagnostics companies</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> facilitated by MRC Technology</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> no such </span><span style="font-family:'Times New Roman'; font-size:11pt">commercial </span><span style="font-family:'Times New Roman'; font-size:11pt">partner was identified. The clear feedback </span><span style="font-family:'Times New Roman'; font-size:11pt">was </span><span style="font-family:'Times New Roman'; font-size:11pt">that further </span><span style="font-family:'Times New Roman'; font-size:11pt">test development and </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">valuation of the test specificity and a UK prevalence study to determine the market for such a test would be needed to make a business case. In order to maintain momentum in translating our technology </span><span style="font-family:'Times New Roman'; font-size:11pt">to protect the public health </span><span style="font-family:'Times New Roman'; font-size:11pt">the Unit has, with additio</span><span style="font-family:'Times New Roman'; font-size:11pt">nal assistance from MRC, confirmed our initial specificity estimates with a much larger control </span><span style="font-family:'Times New Roman'; font-size:11pt">cohort. This study was initiated following discussions with Professor Mark Turner (Chair, Prion Working Group of the National Blood Service) and Dr Lorna Willia</span><span style="font-family:'Times New Roman'; font-size:11pt">mson (Medical &amp; Research Director, NHSBT) regarding the requirements of the UK’s blood services. </span><span style="font-family:'Times New Roman'; font-size:11pt">The NHS Blood and Transfusion (NHSBT), in consultation with other European partners, formalised a common technical specification requiring screening tests achi</span><span style="font-family:'Times New Roman'; font-size:11pt">eve a minimum diagnostic specificity of 99.5% determined from a cohort of 5000 samples</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">37</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">We have now analysed 5000 anonymous donor samples provided by the American Red Cross. This is a cohort of samples from a nation with very low exposure to BSE. The conclusion of this study has been no pos</span><span style="font-family:'Times New Roman'; font-size:11pt">itive reactions from the total of 5000 US samples</span><span style="font-family:'Times New Roman'; font-size:11pt"> demonstrating adequate </span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">pecificity</span><span style="font-family:'Times New Roman'; font-size:11pt"> for our proposal to </span><span style="font-family:'Times New Roman'; font-size:11pt">conduct </span><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">large </span><span style="font-family:'Times New Roman'; font-size:11pt">scale comparison of </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">20,000 </span><span style="font-family:'Times New Roman'; font-size:11pt">anonymous blood samples from </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK and USA.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The establishment of accurate prevalence estimates for </span><span style="font-family:'Times New Roman'; font-size:11pt">prionaemia will provide the essential information to determine if routine screening for vCJD infection in blood donations, and in patients prior to high risk surgical procedures and tissue and organ donation</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> is required. This is not only important from th</span><span style="font-family:'Times New Roman'; font-size:11pt">e perspective of risk management and protecting the health of the public but also to </span><span style="font-family:'Times New Roman'; font-size:11pt">demonstrate a business case to justify the </span><span style="font-family:'Times New Roman'; font-size:11pt">commercial investment required to </span><span style="font-family:'Times New Roman'; font-size:11pt">produce a </span><span style="font-family:'Times New Roman'; font-size:11pt">robust </span><span style="font-family:'Times New Roman'; font-size:11pt">high throughput test from our laboratory prototype.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The primary benefit of co</span><span style="font-family:'Times New Roman'; font-size:11pt">mmercialising the assay would be the availability of a cost-effective screening test for use with donated blood and organs to prevent iatrogenic infection and safeguard the blood supply. The ability to screen human blood may ultimately obviate the need to </span><span style="font-family:'Times New Roman'; font-size:11pt">import frozen plasma from the USA and allow UK based industries to recommence processing and sale of UK sourced plasma and plasma products.</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In addition to routine screening applications, knowledge of the background level of infection in the general populat</span><span style="font-family:'Times New Roman'; font-size:11pt">ion is required for the interpretation of test results if offered to individuals deemed to at risk of iatrogenic disease some of whom have already sought testing. After the successive tragedies of HIV and HCV infection in groups </span><span style="font-family:'Times New Roman'; font-size:11pt">multiply exposed to blood p</span><span style="font-family:'Times New Roman'; font-size:11pt">roducts, </span><span style="font-family:'Times New Roman'; font-size:11pt">there is understandably heightened concern about risks of prion disease transmission in blood products. A useable predictive test in these groups may offer an opportunity both for individuals to resolve issues of personal risk, and for anonymous s</span><span style="font-family:'Times New Roman'; font-size:11pt">tudies to resolve issues of risk for groups of individuals following the formal notification exercise instigated by the HPA. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Finally, the large international research effort on understanding prion diseases since the arrival of BSE has led to them becoming</span><span style="font-family:'Times New Roman'; font-size:11pt"> arguably the best understood cause of dementia. Indeed, there is growing evidence that the fundamental molecular mechanisms seen in prion disease may be relevant for much commoner neurodegenerative diseases such as Alzheimer’s, Parkinson’s and motor neuro</span><span style="font-family:'Times New Roman'; font-size:11pt">ne disease (see</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">38</span><span style="font-family:'Times New Roman'; font-size:11pt"> for lay review). </span><span style="font-family:'Times New Roman'; font-size:11pt">A number of potential therapeutics are in development at the MRC Prion Unit and elsewhere internationally that might allow both effective treatment and post-exposu</span><span style="font-family:'Times New Roman'; font-size:11pt">re prophylaxis to prevent development of clinical disease in healthy but infected individuals.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Reference List</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">1.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge,J. &amp; Clarke,A. A general model of prion strains and their pathogenicity. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Science</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">318</span><span style="font-family:'Times New Roman'; font-size:11pt">, 930-936 (2007).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge,J., Sidle,K.C., Meads,J., Ironside,J., &amp; Hill,A.F. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">383</span><span style="font-family:'Times New Roman'; font-size:11pt">, 685-690 (1996).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">3.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Hill AF </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The same prion strain causes vCJD and BSE. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">89</span><span style="font-family:'Times New Roman'; font-size:11pt">, 448-450 (1997).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">4.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Bruce,M.E. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">389</span><span style="font-family:'Times New Roman'; font-size:11pt">, 498-501 (1997).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">5.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Ghani,A.C., Donnelly,C.A., Ferguson,N.M., &amp; Anderson,R.M. The transmission dynamics of BSE</span><span style="font-family:'Times New Roman'; font-size:11pt"> and vCJD. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. R. Acad. Sci. III</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">325</span><span style="font-family:'Times New Roman'; font-size:11pt">, 37-47 (2002).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">6.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Peden,A.H., Head,M.W., Ritchie,D.L., Bell,J.E., &amp; Ironside,J.W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">364</span><span style="font-family:'Times New Roman'; font-size:11pt">, 527-529 (2004).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">7.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Wroe,S.J. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">368</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2061-2067 (2006).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">8.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Peden,A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Variant CJD infection in the spleen of a neurologically asympt</span><span style="font-family:'Times New Roman'; font-size:11pt">omatic UK adult patient with haemophilia. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Haemophilia</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">16</span><span style="font-family:'Times New Roman'; font-size:11pt">, 296-304 (2010).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">9.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge,J. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Kuru in the 21st century--an acquired human prion disease with very long incubation periods. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">367</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2068-2074 (2006).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">10.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Hill AF </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Species barrier independent prion replication in apparently resistant species. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Proc Natl Acad Sci USA</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">97</span><span style="font-family:'Times New Roman'; font-size:11pt">, 10248-10253 (2000).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">11.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Hill AF, Zeidler,M., Ironside,J., &amp; Collinge J Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lan</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">cet.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">349</span><span style="font-family:'Times New Roman'; font-size:11pt">, 99-100 (1997).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">12.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Wadsworth,J.D. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">358</span><span style="font-family:'Times New Roman'; font-size:11pt">, 171-180 (2001).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">13.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Frosh,A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Analysis of 2000 consecuti</span><span style="font-family:'Times New Roman'; font-size:11pt">ve UK tonsillectomy specimens for disease-related prion protein. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">364</span><span style="font-family:'Times New Roman'; font-size:11pt">, 1260-1262 (2004).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">14.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Hilton,D.A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Pathol.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">203</span><span style="font-family:'Times New Roman'; font-size:11pt">, 733-739 (2004).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">15.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Clewley,J.P.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">338</span><span style="font-family:'Times New Roman'; font-size:11pt">, b1442 (2009).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">16.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">de Marco,M.F., Linehan,J., Gill,O.N., Clewley,J.P., &amp; Brandner,S. Large-scale immunohistoch</span><span style="font-family:'Times New Roman'; font-size:11pt">emical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Pathol</span><span style="font-family:'Times New Roman'; font-size:11pt">(2010).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">17.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Gill,O.N. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale sur</span><span style="font-family:'Times New Roman'; font-size:11pt">vey. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">347</span><span style="font-family:'Times New Roman'; font-size:11pt">, f5675 (2013).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">18.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">SEAC 100/6 Prevalence: Resolving the discrepancy in current estimates. Spongiform Encephalopathy Advisory Committee. 1 April 2008. </span><a href="http://www.seac.gov.uk/papers/paper100-6.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.seac.gov.uk/papers/paper100-6.pdf</span></a></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">19.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">SEAC 100/2 Combining evidence from tissue surveys to estimate prevalence of subclinical vCJD. Spongiform Encephalopathy Advisory Committee. 2008. </span><a href="http://www.seac.gov.uk/papers/paper100-2.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.seac.gov.uk/papers/paper100-2.pdf</span></a></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">20.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge,J. Cell biology. The risk of prion zoonoses. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Science</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">335</span><span style="font-family:'Times New Roman'; font-size:11pt">, 411-413 (2012).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">21.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Llewelyn,C.A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Possible transmission of v</span><span style="font-family:'Times New Roman'; font-size:11pt">ariant Creutzfeldt-Jakob disease by blood transfusion. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">363</span><span style="font-family:'Times New Roman'; font-size:11pt">, 417-421 (2004).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">22.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Houston,F. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prion diseases are efficiently transmitted by blood transfusion in sheep. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Blood</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">112</span><span style="font-family:'Times New Roman'; font-size:11pt">, 4739-4745 (2008).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">23.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Andreoletti,O. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Highly eff</span><span style="font-family:'Times New Roman'; font-size:11pt">icient prion transmission by blood transfusion. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PLoS Pathog</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">8</span><span style="font-family:'Times New Roman'; font-size:11pt">, e1002782 (2012).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">24.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Joiner S, Linehan J, Brandner S, Wadsworth JD, &amp; Collinge J Irregular presence of abnormal prion protein in appendix in variant Creutzfeldt-Jakob disease. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Neurol,Neurosurg and Psych</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">73</span><span style="font-family:'Times New Roman'; font-size:11pt">, 597-598 (2002).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">25.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Beringue,V. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Facilitated Cross-Species Transmission of Prions in Extraneural Tissue. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Science</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">335</span><span style="font-family:'Times New Roman'; font-size:11pt">, 472-475 (2012).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">26.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Palmer,M.S., Dryden,A.J., Hughes,J.T., &amp; Collinge J Homozygous prion </span><span style="font-family:'Times New Roman'; font-size:11pt">protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">352</span><span style="font-family:'Times New Roman'; font-size:11pt">, 340-342 (1991).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">27.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge,J. Molecular neurology of prion disease. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Neurol Neurosurg Psychiatry</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">76</span><span style="font-family:'Times New Roman'; font-size:11pt">, 906-919 (2005).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">28.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Asante,E.A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> BSE prions propagate </span><span style="font-family:'Times New Roman'; font-size:11pt">as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">EMBO J</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">21</span><span style="font-family:'Times New Roman'; font-size:11pt">, 6358-6366 (2002).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">29.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Asante E </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob diseas</span><span style="font-family:'Times New Roman'; font-size:11pt">e in transgenic human prion protein 129 heterozygous mice. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Proc Natl Acad Sci U S A.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">103</span><span style="font-family:'Times New Roman'; font-size:11pt">, 10759-10764 (2006).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">30.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Kaski,D. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Variant CJD in an individual heterozygous for PRNP codon 129. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">374</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2128 (2009).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">31.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Lloyd,S., Mead,S., &amp; Co</span><span style="font-family:'Times New Roman'; font-size:11pt">llinge,J. Genetics of Prion Disease. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Topics in Current Chemistry</span><span style="font-family:'Times New Roman'; font-size:11pt">(2011).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">32.  </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><a href="http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm110516/text/110516w0003.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm110516/text/110516w0003.htm</span></a><span style="font-family:'Times New Roman'; font-size:11pt">. Hansard 16 May 2011. 2011. </span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">33.  </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><a href="http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm110301/text/110301w0003.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.publications.</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">parliament.uk/pa/cm201011/cmhansrd/cm110301/text/110301w0003.htm</span></a><span style="font-family:'Times New Roman'; font-size:11pt">. Hansard 1 Mar 2011. 2011. </span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">34.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Jackson GS </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> An enzyme-detergent method for effective prion decontamination of surgical steel. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J. Gen. Virol.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">86</span><span style="font-family:'Times New Roman'; font-size:11pt">, 869-878 (2005).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">35.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Edgew</span><span style="font-family:'Times New Roman'; font-size:11pt">orth,J.A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J. Gen. Virol.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">92</span><span style="font-family:'Times New Roman'; font-size:11pt">, 718-726 (2011).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">36.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Edgeworth,J.A. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Detection of prion infection in variant Creutzfel</span><span style="font-family:'Times New Roman'; font-size:11pt">dt-Jakob disease: a blood-based assay. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt">(2011).</span></p><p style="margin:0pt 0pt 12pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">37.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Guideline for the CE marking of blood based in vitro diagnostic medical devices for vCJD based on detection of abnormal PrP</span><span style="font-family:'Times New Roman'; font-size:11pt">. European commission DG Health and Consumer Directorate. 2012. </span><a href="http://ec.europa.eu/health/medical-devices/files/meddev/2_14_4_ol_en.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://ec.europa.eu/health/medical-devices/files/meddev/2_14_4_ol_en.pdf</span></a></p><p style="margin:0pt 0pt 0pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">38.   </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Walker,L.C. &amp; Jucker,M. SEEDS OF DEMENTIA A chain reaction of toxic proteins may hel</span><span style="font-family:'Times New Roman'; font-size:11pt">p explain Azheimer's, Parkinson's and other killers-an insight that could lead to desperately needed new treatment options. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Scientific American</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">308</span><span style="font-family:'Times New Roman'; font-size:11pt">, 52-57 (2013).</span></p><p style="margin:0pt 0pt 0pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt 0pt 0pt 45pt; text-align:justify; text-indent:-45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>